Summary. Corticotropin-releasing 
Summary. Corticotropin-releasing (Harris, 1948) . Thereafter, hypothalamic extracts were seen to have CRF activity (Guillemin and Rosemberg, 1955) which since then has been shown to be polymorphic, i.e. shared by arginine vasopressin (AVP1, angiotensin II (A II) and adrenaline. The purification of a molecule comprising 41 amino acids from half a million ovine hypothamami (oCRF) has opened up a vast potential field of research (Vale et al., 19811. ) .
Characterization of 1-41 CRF
The purification of ovine CRF ( O CRF) was rapidly followed by the determination of its primary structure and the synthesis of the molecule (Vale et a/., 19811. ) .
Both extracted and synthetic oCRF's were shown to increase the secretion of ACTH and ¡3-endorphin in vitro in anterior pituitary cell culture and in vivo in rats, and the 10-fold higher activity of the synthetic molecule over natural oCRF has been attributed to the presence of an oxidized methionine residue at C21. oCRF has sequences in common with sauvagine, angiotensinogen and urotensin I, and differs by 7 amino acids .
The cDNA of the oCRF precursor was cloned by Furutani et al., (1983) (Widmaier and Dallman, 1984) , in culture (Buckingham, 1982) , and in pituitary cells suspended in columns (Gaillard et al., 1984) . Sensitivity varies but the in vitro effect appears to be specific for POMC derivatives (Wehrenberg et al., 1984) . Moreover, the action of CRF does not appear to affect ACTH production in the intermediate lobe (Suda et al., 1983 (Rivier and Vale, 1984a) . Repeated oCRF injections at 2-hour intervals lead to a long desensitization phase of about 12 h, after which normal sensitivity reappears in spite of elevated corticosterone levels. Intravenous perfusion has similar effects (Rivier and Vale, 1984a) . However, if the animal is pretreated with anti-CRF antibody, no such increase occurs The intravenous injection of oCRF (0.3 to 30 !g/kg) induces an increase in the levels of ACTH and cortisol with the lowest dose (0.3 pg/kg) on upwards. With doses above 3 !g/kg, the response becomes biphasic with an early peak after 15 min, followed by a slight decrease and a second peak, then a return to base-line levels after 6 h. These doses (3 to 30 !g/kg) are also accompanied by secondary effects such as flushes and dyspnoea which may persist for several hours. When these higher doses are injected late in the afternoon the normallyobserved nocturnal peak disappears . A dose of 30 !g/kg of O CRF, the only dose tested, is also capable of increasing the levels of LPH ((3 + -y) and (3-endorphin ()3-endorphin + (3-LPH) (Jackson et al., 1984) ; these tests were done in the late afternoon.
The magnitude of ACTH and cortisol responses to total doses of 100 ; n g (Tsukada et al., 1983) or 50 wg (Copinschi et al., 1983) (Leroux and Pelletier, 1984) .
The effects of CRF are mediated by the activation of adenyl cyclase. cAMP is increased within the cells and in culture media (Labrie et al., 1984) , the CRF effect is duplicated by 8 Br. cAMP and amplified by GTP (Labrie et al., 1984) and phosphodiesterase inhibitors , Vlaskovska et al., 1984 (Eberwine et aL, 1984) .
The CRF receptors in the anterior pituitary have the following characteristics (Wynn et al., 1983) ; high affinity, Kd = 10-9 M, low capacity, specificity and reversibility. The number of sites changes with the adrenal status. CRF injection may induce a period of desensitization both in vitro (Reisine and Hoffman, 1983) and in vivo (Rivier and Vale, 1984a 1) Effects on the autonomic nervous system. &horbar; Intracerebro-ventricular injection of oCRF into rats results in increased blood pressure and heart rate, effects which are totally inhibited by chlorisondamine, an inhibitor of sympathetic ganglions . A rise in glycemia and in the plasma levels of adrenaline and noradrenaline was also observed . Bilateral adrenalectomy and chlorisondamine abolish these effects, but hypophysectomy does not. The intermediary in these effects of CRF therefore seems to be the activation of the peripheral sympathetic nervous system and, more particularly, the adrenal medulla. A similar type of action is the inhibition of pentagastrin induced gastric acidity (Tache et al., 1983) .
2) Effects on other hypothalamic factors. -Intracisterno-ventricular injection in rats also results in a decrease in circulating GH (Rivier and Vale, 1984c), probably via a stimulation of somatostatin. In gonadectomized rats, the results are diminished base-line levels of LH. These effects are not counteracted by blockage of the sympathetic ganglions or by dexamethasone or naltrexone, and they do not apply to LH stimulation by GnRH. In intact female rats, intraventricular injection of CRF blocks 50 % of the ovulations and 40 % of the gestations (Rivier and Vale, 1984c).
3) Effects on behaviour. &horbar; Finally, central injections of oCRF induce increased activity and emotivity (Sutton et al., 1982) . C) Relationship between CRF and response to stress.
Several arguments support the notion that stress is a stimulatory factor in the production of CRF. Pre-treatment of rats with anti-CRF antibody partially suppresses the ACTH increases induced by various types of stress such as ether anesthesia (Gillies, Linton and Lowry, 1982) . CRF activity is diminished through the presence of anti-VP antibodies. It is low in hypothalamic extracts from Brattleboro rats. /n vivo a similar synergistic action has been observed in man (Liu et al., 1983) and in animals (Rivier et al., 1984a) where it is inhibited by pretreatment with either anti-CRF or anti-VP antibodies or both (Gillies, Linton and Lowry, 1984) . The mechanisms of this synergetic action remain to be discovered. The direct action of VP on ACTH production is not accompanied by any stimulation of cAMP production, whereas the combination of CRF-AVP has a synergistic stimulatory effect on intracellular cAMP (Rivier et al., 1984a) . Nevertheless, a third type of receptor (V 3 ?) may be implicated (Baertschi and Friedli, 1985) .
There is evidence that the specific nature of VP receptors in the anterior pituitary may undergo down-regulation and desensitization (Koch and LutzBucher, 1985 ; Gaillard et al., 1984) .
2) lnteractions between VP and hypothalamic CRF production. &horbar; Plotzky, Bruhn and Vale (1984) Negro-vilar, 1983) . It is nevertheless not impossible that the additive action of All on ACTH production has a central pathway (in contrast with those of CRF and VP) since it disappears in animals pretreated with chlorpromazine, morphine and nembutal (Spinedi and Negro-Vilar, 1983 Reproduction, Nutrition, D6veloppement n° 5&horbar; 1985. &horbar; 7 contrasts with its action on the pituitary whereby ACTH secretion is stimulated via a! receptors (Labrie et al., 1984) and there is an additive effect on CRF action (Giguere and Labrie, 1983) . In turn, CRF stimulates the secretion of both noradrenaline and adrenaline (Brown, Rivier, and Vale, 1984) .
3) Prostaglandins. &horbar; ln vitro stimulation of ACTH production by rat pituitary glands (CRF and AVP) is accompanied by increased PGE 2 concentration in the culture medium. The inhibition of PGE 2 production with indomethacin increases anterior pituitary response, and PGE 2 production is thought to act as a negative feedback modulator (Vlaskovska, Hertting and Keppel, 1984) . C) Interactions with steroids 1) lnteractions between steroids and hypothalamic CRF production. &horbar;
Glucocorticoid feedback control of ACTH secretion is well documented but the site of this action remains unknown. Much of the discussion arises from differences in the means of evaluating hypothalamic and anterior pituitary contents, and interpretations can be ambiguous. Some workers have seen decreases in CRF activity in hypothalamic extracts (biological assay) 8 days after adrenalectomy in rats (Hashimoto et al., 1981) accompanied by increases in both pituitary and plasma ACTH levels. Other workers have reported changes varying with time (an initial decrease followed by an increase during the second week) in the CRF content of the median eminence (radioimmunoassay) and the ACTH content of the anterior pituitary (Suda et al., 1983) .
Nevertheless, certain data argue in favour of the hypothalamus as one of the sites of feedback control :
-ACTH elevation in response to bilateral adrenalectomy is diminished in rats pretreated with anti-CRF antibodies ; -in rats pretreated with dexamethasone, there is a reduction in the flow of CRF in the portal system, stimulated by stress-induced hemorrhage (Plotzky and Vale, 1984) .
Decreases in the CRF content of the hypothalamus are attributed to « initial depletion », followed by a phase of synthesis. In contrast, glucocorticoid treatment results in increases in hypothalamic CRF content, whereas androgens and progesterone have no effect. Aldosterone has a weak glucocorticoid action and oestrogens have a mild stimulatory effect (Buckingham, 1982) .
2) lnteractions between steroids and CRF effects on the pituitary gland. -ln vivo experiments : in rats dexamethasone treatment causes a drop and adrenalectomy a rise in ACTH levels in the anterior pituitary (Hashimoto et al., 19811. ) .
In vitro experiments : ACTH stimulation induced by the action of 2 nmoles of CRF on rat anterior pituitary gland in perifusion is inhibited by (10-6 M) dexamethasone and (10-7 M) cortisol and corticosterone. The time-lag of this inhibition is 10 min which is longer than the 3-min rapid feedback observed in vivo (Widmaier and Dallman, 1984) .
It therefore seems certain that glucocorticoids inhibit CRF-stimulated ACTH production in the anterior pituitary gland, but their mode of action is not clearly understood. It may be independent of adenyl cyclase activation or related to the suppression of this stimulation (Bugnon et al., 1982 (Shibasaki et al., 1982) . A similar substance is also found in the plasma of pregnant women during the last 3 months of pregnancy (Sasaki et al., 1984) . The influence of placental CRF on the adrenal-pituitary function remains to be determined. At term, CRF levels are higher in maternal plasma and in cord venous blood than in arterial blood, suggesting a transfer from the mother to the fetus (Campbell et al., 1985 
